UBS Group AG Increases Stake in Beta Bionics, Inc. $BBNX

UBS Group AG grew its position in Beta Bionics, Inc. (NASDAQ:BBNX) by 96.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 251,438 shares of the company’s stock after acquiring an additional 123,533 shares during the period. UBS Group AG’s holdings in Beta Bionics were worth $7,661,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Essex Investment Management Co. LLC acquired a new stake in Beta Bionics in the third quarter valued at about $4,423,000. JPMorgan Chase & Co. increased its position in Beta Bionics by 3,238.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock worth $4,092,000 after purchasing an additional 199,785 shares during the period. Pura Vida Investments LLC increased its position in Beta Bionics by 11,150.0% during the 3rd quarter. Pura Vida Investments LLC now owns 281,250 shares of the company’s stock worth $5,588,000 after purchasing an additional 278,750 shares during the period. SG Americas Securities LLC purchased a new position in shares of Beta Bionics during the 4th quarter worth approximately $4,579,000. Finally, Farallon Capital Management LLC raised its stake in shares of Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after buying an additional 110,000 shares in the last quarter.

Beta Bionics Price Performance

BBNX opened at $9.40 on Tuesday. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a market cap of $418.86 million, a P/E ratio of -6.23 and a beta of 3.29. The stock’s 50 day simple moving average is $10.61 and its 200 day simple moving average is $18.61.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. The firm had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. Research analysts expect that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Analyst Ratings Changes

BBNX has been the topic of a number of analyst reports. Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. The Goldman Sachs Group cut their price objective on Beta Bionics from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Weiss Ratings downgraded Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Truist Financial lowered their price target on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Finally, UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.00.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.